Skip to main content

Table 4 Integration of the summary the DVH analysis for the clinical cases of the two open-loop validations

From: Assessment of a model based optimization engine for volumetric modulated arc therapy for patients with advanced hepatocellular cancer

Validation on the independent sample of 25 patients Clinical plans Open-loop validation I Open-loop validation II p
PTV: Mean [%] 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 I: NS
[0.0-0.0] [0.0-0.0] [0.0-0.0] II: NS
PTV: D1% [%] 106.8 ± 2.4 107.6 ± 2.3 105.4 ± 1.0 I:<0.05
[103.5-114.3] [104.3-112.6] [103.1-107.0] II:<0.05
PTV: D99% [%] 90.0 ± 2.5 90.2 ± 3.7 92.8 ± 3.8 I:NS
[82.6-93.5] [79.4-94.8] [80.4-95.9] II:<0.05
PTV: HI 0.13 ± 0.04 0.12 ± 0.04 0.08 ± 0.02 I:NS
[0.07-0.23] [0.06-0.20] [0.05-0.15] II:<0.01
PTV: CI 1.11 ± 0.07 1.08 ± 0.05 1.05 ± 0.04 I:<0.05
[1.05-1.21] [1.01-1.13] [1.00-1.11] II:<0.01
Normal liver: Mean dose [Gy] 15.6 ± 5.5 15.4 ± 5.1 16.4 ± 5.4 I: NS
[5.8-23.5] [6.2-23.0] [6.9-23.8] II: <0.05
Spine: Mean dose [Gy] 9.2 ± 4.5 8.2 ± 4.9 6.6 ± 3.5 I: <0.05
[1.0-19.7] [0.9-19.9] [0.8-15.5] II: <0.01
Left kidney Mean dose [Gy] 3.9 ± 3.1 2.5 ± 2.1 2.0 ± 1.7 I: <0.01
[0.2-12.7] [0.2-9.2] [0.1-7.5] II: <0.01
Right kidney Mean dose [Gy] 7.9 ± 5.8 6.3 ± 4.8 5.6 ± 4.0 I: <0.01
[0.7-18.9] [0.6-14.6] [0.8-12.6] II: <0.01
Stomach Mean dose [Gy] 10.9 ± 2.9 9.2 ± 4.5 9.4 ± 3.5 I: <0.05
[5.8-16.1] [3.8-20.8] [3.6-15.9] II: <0.05
Esophagus: Mean dose [Gy] 17.8 ± 8.2 13.9 ± 7.4 10.9 ± 3.9 I: <0.05
[4.9-38.2] [3.8-34.1] [4.6-18.0] II: <0.01
Body-PTV: V10Gy [%] 17.1 ± 8.1 16.7 ± 7.9 16.8 ± 7.6 I: <0.10
[2.6-31.5] [2.6-32.9] [3.1-32.3] II: <0.10
  1. For the PTV, conformity Index CI is defined as the ration between V95% and PTV. Homogeneity index HI is defined as (D5-D95)/Mean.
  2. VxGy Volume receiving at least XGy, D Y% (D ycm3 ) dose delivered to at least Y% (or cm3) of the volume. CI Conformity Index, HI homogeneity Index, NS not significant. I: clinical vs. Open-loop I; II: clinical vs. Open-loop II.